Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CITADEL: Baltaleucel-T in Aggressive EBV+ Extranodal NK/T-cell Lymphoma
NCT01948180Phase 2Terminated
- Sponsor
- Kuur Therapeutics
- Start
- Sep 2014
- Primary completion
- Apr 2018
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Native Immune Cells
- Countries
- 4
01
Overview
A Phase 2 trial of baltaleucel-T in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Kuur Therapeutics. Started Sep 2014; status: terminated.
02
Drugs
baltaleucel-T
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT01948180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01948180.